Chester County News and Community Website
WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, will participate in the Citizens Life Sciences Conference in New York on May 7, 2025.
Prelude Therapeutics to Host Fireside Chat at Citizens Life Sciences Conference 2025 Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) showcased significant advancements in its oncology research at the American Association for Cancer Research (AACR) Annual Meeting, unveiling preclinical findings for its …
Prelude Therapeutics Unveils Promising Preclinical Data on Novel Cancer Therapies Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has released its 2024 financial results and provided an update on its clinical pipeline, underscoring significant progress in its precision oncology programs. The …
Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline Advancements Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has announced its participation in the Barclays 27th Annual Global Healthcare Conference, set to take place on March 11, 2025, in Miami, FL.
Prelude Therapeutics to Present at Barclays Global Healthcare Conference Read More WILMINGTON, DE — Prelude Therapeutics (Nasdaq: PRLD) presented encouraging interim results from its Phase 1 trial of PRT2527, an investigational CDK9 inhibitor, at the 66th American Society of Hematology Annual Meeting. …
Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, has shared its third-quarter 2024 financial results alongside significant updates on its clinical pipeline. The company continues to …
Prelude Therapeutics Reports Q3 2024 Results and Clinical Progress Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has unveiled encouraging results from its ongoing Phase 1 trial of PRT3789, a groundbreaking SMARCA2 degrader, at the 36th Annual EORTC-NCI-AACR Symposium …
Prelude Therapeutics Shares Promising Phase 1 Trial Data for PRT3789 at International Symposium Read More WILMINGTON, DE — Prelude Therapeutics Incorporated this week unveiled interim results from its Phase 1 trial of PRT3789, a pioneering therapy designed to target cancers with a SMARCA4 mutation. The data, …
Prelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer Treatment Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD) has revealed groundbreaking clinical data on its novel therapeutic agent, PRT3789, at the European Society of Medical Oncology (ESMO) Congress 2024 in Barcelona. …
Prelude Therapeutics Unveils Promising Data on PRT3789 at ESMO Congress 2024 Read More WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, reported its financial results for the second quarter ending June 30, 2024. The company also provided significant …
Prelude Therapeutics Reports Q2 Financial Results and Key Clinical Developments Read More